Study on combined therapy with fluvastatin and fenofibrate in patients with combined hyperlipidemia

Objective To investigate the effcacy and safety of combined therapy with fluvastatin andfenofibrate in patients with combined hyperlipidemia. Result Select January 2007-December 2008 in our hospital out-patient cardiac medicine in patients with mixed hyperlipidemia were randomly divided into 180 cases of fluvastatin group,fenofibrate group,combination therapy group 60 cases; Fluvastatin group nightly 40mg oral fluvastatin,fenofibrate group night oral fenofibrate 200mg,combined daily morning oral fenofibrate 200mg,late oral fluvastatin 20mg,both use to 12 weeks. Observed changes in lipid parameters,efficacy evaluation of major adverse drug. Method Three group TC,LDL-C,TG no difference before treatment (P0.05),fluvastatin group after treatment,TC,LDL-C were significantly decreased (P0.05),TG did not change significantly (P0.05 ); Fenofibrate treatment group TG were significantly decreased (P 0.05),TC,LDL-C did not change significantly (P0.05);combined medication group TC,LDL-C,TG were significantly decreased (P0.05). Combined clinical control (markedly improved) 83.3% (50/60) than in fluvastatin group 68.3% (41/60),fenofibrate group 65.0%. Three groups of serum CK,liver and renal function parameters such as no significant changes in symptoms of myopathy does not appear,no exit or termination of Example. Conclusions Combination therapy with fluvastatin and fenofibrate is more effective than fluvastatin monotherapy in patientswith combined hyperlipidemia￡﹁and is generally safe and well tolerated.